Oncology

New therapeutic target may decrease breast cancer risk.

Treatment with dabrafenib and trametinib extends patient survival more than 2 years.

Research offers enhanced method to assess effects of cancer drugs on normal and healthy cells.

New approach may stop growth and kill cancer cells.

Luteolin may carry significant anti-tumor effects.

Patients treated with atezolizumab lived an average of 7.7 months longer than people treated with docetaxel chemotherapy.

Desmoplasmic melanoma possesses a mutation that protects tumors from destruction by the immune system.

Top news of the week in oncology drug development.

Discovery could lead to treatments that stop cancer recurrence.

Top stories of the week on Specialty Pharmacy Times.

Expansion covers patients who have greater than 30% myeloblasts.

Average time for withdrawals in colonoscopies came in at approximately 8.6 minutes.

Intralesional interleukin-2 shows promise in cutaneous melanoma metastases.

Technology may help improve patient outcomes through enhanced personalized medicine.

Nanopore technology may soon be adapted for early disease detection.

Bristol-Myers Squibb will take part in Leerink Partners Immuno-Oncology Roundtable on October 1.

Findings could eliminate need for weeks of treatments that carry severe side effects.

Research may help tailor treatments to individual patients.

Average reimbursement for Part B oncology drugs is 52% higher in 340B hospitals than in community cancer clinics.

Treatment seeks to reverse chemotherapy resistance caused by P-glycoprotein.

Chronic lymphocytic leukemia treatment reprograms T cells to hunt and kill cancer cells.

Newly discovered epigenetic markers offer hope.

Study reveals targets on the tumor cell that can be recognized by killer T-cells.

Top recent developments in cancer research.

Lymphoma and lung cancer present significant risk to RA patients.

Research will lead to novel viral and immunologic treatments.

Combination of immunotherapy and aspirin showed a substantial decrease in bowel and melanoma skin cancer growth in mice.

Genetic variants regulate immune cells with important roles in immunodeficiency disorders.